GSDME

Across TCGA pan-cancer cohorts, GSDME mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSDME data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GSDME mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GSDME expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where GSDME mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.429	0.867	.003	60	view →
UCEC	OS	Median	II,III,IV	0.638	1.000	.014	16	view →
PDAC	DFS	Tertile	III,IV	0.515	0.984	.019	7	view →
LSCC	OS	Quartile	All	0.677	0.893	.014	4	view →
HNSC	DFS	Median	IV	0.800	0.580	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSDME–CCRCC (DFS)

Open the CCRCC breakdown →